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Abstract
Introduction: Gefitinib and erlotinib have minor differences in their chemical structures, and thus it remains
unclear whether the hepatotoxicity induced by one compound is affected by the other. The case of a patient who
developed erlotinib-induced liver injury and was then treated with gefitinib without hepatic toxicity or disease
progression is presented.
Case presentation: A 31-year-old Japanese woman, who never smoked and who was diagnosed as having lung
adenocarcinoma with carcinomatous meningitis, was treated with erlotinib. She developed erlotinib-induced liver
injury after four weeks of treatment. The treatment was stopped right away, but the symptoms of meningitis re-
appeared immediately. Gefitinib treatment was started and continued without recurrence of drug-induced liver
injury.
Conclusion: Gefitinib appears to be a potential treatment option after erlotinib-induced liver injury.
Introduction
Gefitinib and erlotinib were the first oral epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-
TKIs) to become available in clinical practice. They have
come to be very important drugs for patients with non-
small cell lung cancer (NSCLC) harboring sensitive
mutations of EGFR [1,2]. They have minor differences
in their chemical structures, and thus it remains unclear
whether the hepatotoxicity induced by one compound is
affected by the other. The case of a patient who devel-
oped erlotinib-induced liver injury and was then treated
with gefitinib without hepatic toxicity or disease pro-
gression is presented.
Case presentation
A 31-year-old Japanese woman who never smoked pre-
sented with severe headache and nausea, and a perfor-
mance status of approximately three. Gadolinium-
enhanced magnetic resonance imaging (MRI) of her
brain confirmed multiple metastatic brain tumors and
meningitis, and a computed tomography (CT) scan of
the chest confirmed a solitary, spiculated lesion in the
left upper lung lobe. She had normal liver and renal
functions, and she had no history of liver disease, exces-
sive alcohol intake, drug abuse, or hepatitis. Cytology of
the transbronchial brushings of the left upper lobe and
the cerebrospinal fluid obtained by lumbar puncture
revealed adenocarcinoma, and she was diagnosed as
having a primary NSCLC with multiple brain metastases
and carcinomatous meningitis. EGFR gene mutation
analysis did not show the presence of any mutation. She
was started on erlotinib 150 mg orally once daily
because she refused to receive the emetic regimen. Two
weeks after starting treatment, her headache and nausea
had disappeared, and an MRI revealed brain tumor
shrinkage and improvement in the meningitis. However,
about four weeks after starting erlotinib, her transami-
nase levels started to increase, peaking at 972 U/L for
aspartate aminotransferase (AST) and 3,130 U/L for ala-
nine aminotransferase (ALT) (Figure 1). The patient had
not complained of any clinical symptoms such as fever,
nausea, diarrhea, abdominal pain, or fatigue, and she
had taken no other medications or supplements. Serolo-
gic testing for hepatitis B and C was negative. An
abdominal MRI revealed a normal liver with no other
substantial abnormalities. Thus, erlotinib-induced liver
injury was suspected and treatment was discontinued.
After stopping erlotinib, her transaminase levels began
to normalize at once, but severe nausea and headache
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once daily was started with careful monitoring of liver
function. Her nausea and headache improved quickly,
and she continued to take gefitinib for more than 15
weeks without hepatic toxicity or disease progression.
She was lost to follow-up, and she died of her cancer at
another hospital.
Discussion
Erlotinib and gefitinib are orally bioavailable, synthetic
anilinoquinazolines that selectively and reversibly bind
to the intracellular ATP-binding site of EGFR tyrosine
kinase (Figure 2) [1,2]. The hepatotoxicity of both drugs
is usually mild to moderate and reversible on cessation
of the drug. In Japan, Inoue et al. reported that, in a
survey of 3000 NSCLC patients treated with gefitinib,
1.8% of patients developed grade 3 or 4 liver dysfunction
or damage (with elevation of hepatic enzymes) [3].
Additionally, a prospective analysis of a gefitinib investi-
gation reported that 11.1% of 3322 patients had suffered
all-grade liver injury, and most of them were mild [4].
Erlotinib and gefitinib are both based on a 4-anilino-
quinazoline kinase pharmacophore and exhibit similar
pharmacokinetic characteristics in humans after oral
Figure 1 Levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) during erlotinib therapy and subsequent
gefitinib therapy in a 31-year-old Japanese woman with non-small cell lung cancer (NSCLC).
Figure 2 Chemical structures of gefitinib and erlotinib.
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cytochrome P450 (CYP) 3A4 in liver; hepatotoxicities
were common but mild in many cases [3-6]. In our
patient, we were concerned about the possibility of
drug-induced liver injury recurring while on gefitinib. It
is well known that re-challenge or re-administration of
the suspect drug following possible drug-induced liver
injury can result in death or serious liver injury within a
month [7]. The US Food and Drug Administration
(FDA) recommends that re-challenge of subjects with
significant (over 5 times the normal upper limit) transa-
minase elevations should not be attempted [8]. However,
gefitinib did not result in the appearance of drug-
induced liver injury in our patient. There have been
similar reports regarding erlotinib treatment following
gefitinib-induced liver injury [9,10]. Ku et al. hypothe-
sized that, while the pharmacokinetics and basic chemi-
cal structures of both compounds are similar, minor
differences in the chemical structure may account for
differences in hepatotoxicity. They concluded that, in
patients who develop gefitinib-induced hepatotoxicity
but who are otherwise continuing to experience clinical
benefit, consideration can be given to transitioning these
patients to erlotinib [10]. In our patient, the opposite
situation occurred, in that she developed liver toxicity
on erlotinib and was successfully transitioned to gefiti-
nib. Li et al. have examined the enzyme kinetics of gefi-
tinib and erlotinib metabolism by individual CYP
enzymes [11]. They found that gefitinib is more suscep-
tible to CYP3A-mediated metabolism than erlotinib, and
CYP2D6 was involved in gefitinib metabolism to a large
extent, whereas CYP1A2 was extensively involved in
erlotinib metabolism. These different metabolizing
enzyme profiles may affect the drug-induced liver injury
seen with each drug.
Conclusion
Erlotinib and gefitinib are very important drugs for
patients with NSCLC harboring sensitive mutations of
EGFR. Following discontinuation of an EGFR-TKI due
to hepatitis, the benefits and risks of other EGFR-TKI
treatments should be considered. If the potential bene-
fits outweigh the possible risks, and with appropriate
monitoring, evaluating the safety of another EGFR-TKI
may be warranted.
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